FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387380926> ?p ?o ?g. }

• W4387380926 abstract "Abstract Disclosure: C.L. Roth: Other; Self; Received research support from Rhythm Pharmaceuticals, Inc. A.H. Shoemaker: Advisory Board Member; Self; Received payments from Rhythm Pharmaceuticals, Inc and Saniona for advisory boards and lectures. Other; Self; Received research support from Rhythm Pharmaceuticals, Inc. M. Gottschalk: Advisory Board Member; Self; Received compensation for consulting and participation on advisory boards from Rhythm Pharmaceuticals, Inc. Other; Self; Received funding for clinical trials from Rhythm Pharmaceuticals, Inc. J. Miller: Other; Self; Received research support from Harmony Biosciences, Rhythm Pharmaceuticals, Inc, Soleno Therapeutics, and Tryp Therapeutics. G. Yuan: Employee; Self; Employee of Rhythm Pharmaceuticals, Inc. Stock Owner; Self; Has company-awarded RSU and options. S. Malhotra: Employee; Self; Employee of Rhythm Pharmaceuticals, Inc. Stock Owner; Self; Stockholder in in Rhythm Pharmaceuticals, Inc. C. Scimia: Employee; Self; Employee of Rhythm Pharmaceuticals, Inc. Stock Owner; Self; Has company-awarded RSU and options. M. Abuzzahab: Advisory Board Member; Self; Received compensation for advisory board participation from Consynance, Endo Pharmaceutical, Pfizer, and Rhythm Pharmaceuticals, Inc. Consulting Fee; Self; Received compensation for consulting from Consynance, Endo Pharmaceutical, Pfizer, and Rhythm Pharmaceuticals, Inc. Speaker; Self; Received compensation for speaking engagements from Consynance, Endo Pharmaceutical, Pfizer, and Rhythm Pharmaceuticals, Inc. Other; Self; Received research support from Ascendis, Levo Pharmaceuticals, Lumos, NovoNordisk, Rhythm Pharmaceuticals, Inc, Saniona, and Soleno. Background: Hypothalamic obesity (HO) is an acquired form of severe obesity characterized by rapid and excessive weight gain resulting from insult to the hypothalamus—primarily caused by tumor invasion, resection, or radiotherapy—that can impair melanocortin-4 receptor (MC4R) pathway signaling. Treatment with setmelanotide, an MC4R agonist, resulted in weight loss and hunger reduction at 16 weeks in a Phase 2 trial of patients with HO. Here, we report changes in age-appropriate weight-related parameters after 6 months of treatment with setmelanotide in patients with HO who entered a long-term extension (LTE) trial. Methods: A Phase 2, multicenter, open-label study (NCT04725240) examined the efficacy and safety of 16-week setmelanotide treatment in patients aged ≥6 to ≤40 years with a clinical diagnosis of HO. Patients who met the primary endpoint of ≥5% body mass index (BMI) reduction from baseline at Week 16 or experienced investigator-determined clinically meaningful benefit and demonstrated adequate safety were eligible to enroll in the LTE trial (NCT03651765). We assessed the proportion of patients who achieved ≥10% BMI reduction as well as changes in age-appropriate weight-related parameters (ie, mean percent change in body weight for adults [aged ≥18 years] and mean change in BMI Z score and percent of the 95th BMI percentile [%BMI95] for children [aged &lt;18 years]) from index trial baseline to Month 6 of setmelanotide treatment. Results: Of 18 patients originally enrolled in the index trial, 14 (77.8%) continued into the LTE and 13 (72.2%) had received ≥6 months of setmelanotide treatment at the time of this analysis. HO was diagnosed in these patients secondary to treatment of craniopharyngioma (n=11), hypothalamic hamartoma (n=1), and juvenile pilocytic astrocytoma (n=1). At Month 6, 11 of 13 patients (84.6% [90% confidence interval, 59.0%–97.2%) achieved ≥10% BMI reduction from index trial baseline; the remaining 2 patients achieved ≥5% reduction from baseline at Month 6. In adults (n=2), the mean (standard deviation [SD]) percent change in body weight from baseline to Month 6 was −16.2% (7.2%). In children (n=11), the mean (SD) change from baseline in BMI Z score was −1.7 (1.1) and in %BMI95 was −34.8 (14.9) percentage points at Month 6. The most frequent adverse events were nausea (n=9 [69.2%]), skin hyperpigmentation (n=5 [38.5%]), and vomiting (n=4 [30.8%]). Four serious adverse events were reported in 2 patients (Clostridium difficile colitis in 1 patient; malaise, septic shock, and influenza in 1 patient) and were determined not related or unlikely related to study drug. Conclusions: In a heterogeneous population of patients with HO secondary to treatment of hypothalamic tumors, 6 months of setmelanotide treatment was associated with sustained meaningful improvements in weight and BMI with no new safety signals. Presentation: Saturday, June 17, 2023" @default.
• W4387380926 created "2023-10-06" @default.
• W4387380926 creator A5000179221 @default.
• W4387380926 creator A5012630793 @default.
• W4387380926 creator A5020228435 @default.
• W4387380926 creator A5039874120 @default.
• W4387380926 creator A5069805093 @default.
• W4387380926 creator A5070703807 @default.
• W4387380926 creator A5081175353 @default.
• W4387380926 creator A5091178604 @default.
• W4387380926 date "2023-10-01" @default.
• W4387380926 modified "2023-10-07" @default.
• W4387380926 title "SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity" @default.
• W4387380926 doi "https://doi.org/10.1210/jendso/bvad114.104" @default.
• W4387380926 hasPublicationYear "2023" @default.
• W4387380926 type Work @default.
• W4387380926 citedByCount "0" @default.
• W4387380926 crossrefType "journal-article" @default.
• W4387380926 hasAuthorship W4387380926A5000179221 @default.
• W4387380926 hasAuthorship W4387380926A5012630793 @default.
• W4387380926 hasAuthorship W4387380926A5020228435 @default.
• W4387380926 hasAuthorship W4387380926A5039874120 @default.
• W4387380926 hasAuthorship W4387380926A5069805093 @default.
• W4387380926 hasAuthorship W4387380926A5070703807 @default.
• W4387380926 hasAuthorship W4387380926A5081175353 @default.
• W4387380926 hasAuthorship W4387380926A5091178604 @default.
• W4387380926 hasBestOaLocation W43873809261 @default.
• W4387380926 hasConcept C10138342 @default.
• W4387380926 hasConcept C120757647 @default.
• W4387380926 hasConcept C126322002 @default.
• W4387380926 hasConcept C135343436 @default.
• W4387380926 hasConcept C144133560 @default.
• W4387380926 hasConcept C15744967 @default.
• W4387380926 hasConcept C3017619653 @default.
• W4387380926 hasConcept C39389867 @default.
• W4387380926 hasConcept C71924100 @default.
• W4387380926 hasConceptScore W4387380926C10138342 @default.
• W4387380926 hasConceptScore W4387380926C120757647 @default.
• W4387380926 hasConceptScore W4387380926C126322002 @default.
• W4387380926 hasConceptScore W4387380926C135343436 @default.
• W4387380926 hasConceptScore W4387380926C144133560 @default.
• W4387380926 hasConceptScore W4387380926C15744967 @default.
• W4387380926 hasConceptScore W4387380926C3017619653 @default.
• W4387380926 hasConceptScore W4387380926C39389867 @default.
• W4387380926 hasConceptScore W4387380926C71924100 @default.
• W4387380926 hasIssue "Supplement_1" @default.
• W4387380926 hasLocation W43873809261 @default.
• W4387380926 hasOpenAccess W4387380926 @default.
• W4387380926 hasPrimaryLocation W43873809261 @default.
• W4387380926 hasRelatedWork W2027715794 @default.
• W4387380926 hasRelatedWork W2064134577 @default.
• W4387380926 hasRelatedWork W2072492413 @default.
• W4387380926 hasRelatedWork W2373995729 @default.
• W4387380926 hasRelatedWork W2393707162 @default.
• W4387380926 hasRelatedWork W2748952813 @default.
• W4387380926 hasRelatedWork W2899084033 @default.
• W4387380926 hasRelatedWork W2997159972 @default.
• W4387380926 hasRelatedWork W3203096336 @default.
• W4387380926 hasRelatedWork W4296378967 @default.
• W4387380926 hasVolume "7" @default.
• W4387380926 isParatext "false" @default.
• W4387380926 isRetracted "false" @default.
• W4387380926 workType "article" @default.